Malaria is still a public health problem in Indonesia. The clinical manifestation of malaria is varied, and many factors may influence its clinical manifestation. Despite the species of malaria, density of parasitemia is known related to the severity or malignancy of malaria. It is worth to analyse the clinical and laboratory data of malaria cases in monitoring dihydroartemisinin-piperaquine (D…
Background. Since 2004, Malaria Program in Indonesia has used Artemisinin Combination Therapy (ACT) to replace the chloroquine resistance. The recommended ACT is Artesunate dan Amodiaquine (AAQ) combination for uncomplicated falciparum malaria. To relieve side effects and clinical complaints of malaria , health workers usually gave symptomatic and other drugs in addition to antimalarial drugs.…
Since 2008, Dihydroartemisinin-Piperaquine (DHP) has been used as the first-line drug for treatment of falciparum malaria in Papua, which gradually will also be used in other endemic areas. The objective of the study was to determine the safety and efficacy of DHP. Patients with uncomplicated malaria due to Plasmodium falciparum were enrolled and treated with supervised DHP (arterakin ®, no. …
The development of DHF patient usually assessed base on clinical condition, platelet count and haematocrit value as the DSS indicators. While leukocyte count is irrespective though leucopenia is common in viral infection. Therefore, further analysis was run to determine whether leucopenia could be as a predictor of DSS This study was a retrospective study with a case control (1:2) design usi…
Background: Clinical and parasitological response of malaria treatment on day 3 follow-up (D3) is a crucial condition to predict the successful of treatment. D3 is a period time that Early Treatment Failure may happen which may cause severe or complicated malaria. Moreover, if the asexual parasitemia is still detected more than 10% study subjects, it is assumed parasites resistance against arte…
Plasmodium vivax malaria resistant to chloroquinenis alarming in Indonesia and has been also reported in other countries. An alternative drug is needed. The study was a prospective evaluation and a comparative study of the therapeutic efficacy of choloquine 25 mg base/kg bw for 3 days (CQ3 plus sulfadoxine-pyrimethamine based on pyrimethamine of 1.23 mg/kg bw single dose (SPI) [CQ3=SPI, n=84] a…